NEX-I develops innovative treatments to improve the quality of life for patients and their family.
NEX-I drives a paradigm shift from the current regime of standard of care in anti-cancer therapies to provide new clinical values.
Through next-generation discovery platform, NEX-I designs assessment tools for the target efficacy of First-In-Class cancer immunotherapy.